MARKET

AYLA

AYLA

Ayala Pharmaceuticals, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.15
+0.05
+0.38%
Closed 16:00 01/22 EST
OPEN
12.75
PREV CLOSE
13.10
HIGH
13.90
LOW
12.70
VOLUME
34.69K
TURNOVER
--
52 WEEK HIGH
16.50
52 WEEK LOW
8.62
MARKET CAP
168.03M
P/E (TTM)
-7.4865
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Ayala Pharmaceuticals (AYLA) Soars: Stock Adds 13.2% in Session
Zacks.com · 4d ago
Ayala Pharmaceuticals (AYLA) Receives a Buy from Raymond James
Raymond James analyst Dane Leone maintained a Buy rating on Ayala Pharmaceuticals (AYLA) today. The company's shares closed last Wednesday at $12.60.
SmarterAnalyst · 01/13 21:35
Ayala Pharmaceuticals to Present at Noble Capital Markets 17th Annual Small & Microcap Virtual Investor Conference
GlobeNewswire · 01/13 21:01
Ayala Pharmaceuticals to Present at the Virtual H.C. Wainwright Bioconnect Conference
GlobeNewswire · 01/05 13:00
Ayala Pharmaceuticals to proceed with Phase 2/3 stage of cancer study
Announcing the completion of the end-of-Phase 1 meeting with the FDA, Ayala Pharmaceuticals ([[AYLA]] -6.6%) says the regulator has granted the company to proceed with the Phase 2/3 pivotal study for AL102
Seekingalpha · 01/04 14:22
Ayala Pharmaceuticals To Accelerate Development Of AL102 For Treatment Of Desmoid Tumors In Pivotal Phase 2/3 Study
- FDA Agreement from End-of-Phase 1 Meeting to Advance to Potential Registrational Study - - Pivotal Trial Expected to Initiate in 1H21 - REHOVOT, Israel & WILMINGTON, Del., Jan. 04, 2021 (GLOBE NEWSWIRE) --
FDA Agreement from End-of-Phase 1 Meeting to Advance to Potential Registrational Study - - Pivotal Trial Expected to Initiate in 1H21 - REHOVOT, Israel & WILMINGTON, Del., Jan. 04, 2021 (GLOBE NEWSWIRE) -- · 01/04 13:02
Ayala Pharmaceuticals to Accelerate Development of AL102 for the Treatment of Desmoid Tumors in Pivotal Phase 2/3 Study
\- FDA Agreement from End-of-Phase 1 Meeting to Advance to Potential Registrational Study -\- Pivotal Trial Expected to Initiate in 1H21 -REHOVOT, Israel & WILMINGTON, Del., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a cl...
GlobeNewswire · 01/04 13:00
Is Ayala Pharmaceuticals, Inc. (AYLA) A Good Stock To Buy?
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually don’t make them change their opinion towards a company. This time it may be different. The coronavirus...
Insider Monkey · 11/27/2020 01:15
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AYLA. Analyze the recent business situations of Ayala Pharmaceuticals, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AYLA stock price target is 21.60 with a high estimate of 29.00 and a low estimate of 12.00.
EPS
Institutional Holdings
Institutions: 11
Institutional Holdings: 2.44M
% Owned: 19.06%
Shares Outstanding: 12.78M
TypeInstitutionsShares
Increased
1
45.42K
New
6
-115.56K
Decreased
2
81.53K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About AYLA
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company. It is focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The Company’s portfolio of product candidates include AL101 and AL102, which targets the aberrant activation of the Notch pathway with gamma secretase inhibitors. The Company’s lead product candidate, AL101, is being developed as a potent, selective, injectable small molecule gamma secretase inhibitor (GSI). It is evaluating AL101 as a monotherapy in an open-label Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma (R/M ACC) for patients bearing Notch-activating mutations. The Company refer this trial as the ACCURACY trial. The Company uses advanced sequencing to identify patients with Notch-activating mutations, an approach that will enable it to target the patient population with cancers.
More

Webull offers kinds of Ayala Pharmaceuticals Inc stock information, including NASDAQ:AYLA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AYLA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AYLA stock methods without spending real money on the virtual paper trading platform.